• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Monoclonal Antibodies As Therapeutic Agents In Oncology And
 

Monoclonal Antibodies As Therapeutic Agents In Oncology And

on

  • 2,740 views

 

Statistics

Views

Total Views
2,740
Views on SlideShare
2,736
Embed Views
4

Actions

Likes
0
Downloads
155
Comments
0

1 Embed 4

http://www.slideshare.net 4

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Monoclonal Antibodies As Therapeutic Agents In Oncology And Monoclonal Antibodies As Therapeutic Agents In Oncology And Presentation Transcript

    • Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy
      Misbahul_ferdous@yahoo.com
    • PRESENATATION BY
      DR MISBAHUL FERDOUS
      MBBS - 2007
      FMD (USTC) 2009
      PGT (CARDIOLOGY) 2008 NICVD
      NATINAL INSTITUTE OF CARDIOVASCULAR
      DISEASES AND HOSPITAL. DHAKA .BANGLADESH
      MD,CARDIOLOGY (COURSE) SHANDONG UNIVERSITY
      School of medicine
      CHINA
    • Key words
      Monoclonal antibody
      Oncology
      Antibody gene therapy
    • What is a monoclonal antibody
      A monoclonal antibody is a laboratory-produced molecule that's carefully engineered to attach to specific defects in your cancer cells.
      Monoclonal antibodies are proteins produced in the laboratory from a single clone of a B cell, the type of cells of the immune system that make antibodies
    • How do monoclonal antibody drugs work?
      1.Make the cancer cell more visible to the immune system:
      The immune system attacks foreign invaders in your body, but it doesn't always recognize cancer cells as enemies. A monoclonal antibody can be directed to attach to certain parts of a cancer cell. In this way, the antibody marks the cancer cell and makes it easier for the immune system to find.
      2. Block growth signals
    • 3.Deliver radiation to cancer cells: By combining a radioactive particle with a monoclonal antibody, doctors can deliver radiation directly to the cancer cells.
    • Side effects of monoclonal antibody
      In general, the more common side effects caused by monoclonal antibody drugs include:
      Allergic reactions, such as hives or itching
      Flu-like symptoms, including chills, fatigue, fever, and muscle aches and pains
      Nausea
      Diarrhea
      Skin rashes
    • Rare, but more serious side effects of monoclonal antibody therapy may include:
      Infusion reactions. Severe allergy-like reactions can occur and in very few cases lead to death.
      Dangerously low blood cell counts. Low levels of red blood cells, white blood cells and platelets may lead to serious complications.
      Skin problems
      Bleeding. Some of the monoclonal antibody drugs are designed to stop cancer from forming new blood vessels. There have been reports that these medications can cause bleeding.
    • Gene therapy
      GENE THERAPY is a field of medicine in which genes are introduced into the body to cure diseases.
      It invovelves :
      Detection of gene
      2) Determination & its role
      3) Isolation & cloning
      4) Introducing the gene by proper way.
      it is of two types :
      (a) germline gene therapy [done in germcells]
      (b) somatic gene therapy [done in somatic cells]
    • humanized monoclonal antibody
      A type of antibody made in the laboratory by combining a human antibody with a small part of a mouse or rat monoclonal antibody. The mouse or rat part of the antibody binds to the target antigen, and the human part makes it less likely to be destroyed by the body's immune system.
    • chimeric antibody
      V domains
      Mouse
      Chimeric
      Human
      C domains
      • rituximab (Rituxan®, anti-CD20), for treatment of lymphoma
      • infliximab (Remicade®, anti-TNF), for treatment of arthritis
    • How do cancer cells differ from normal?
      • Clonal in origin
      • Deregulated growth and lifespan
      • Altered tissue affinity
      • Resistance to control via apoptotic signals
      • Change in surface phenotype and markers
      • Structural and biochemical changes
      • Presence of tumour-specific antigens
    • Prevalence of cancer in UK
    • Men710,040
      Women662,870
      2005 Estimated US Cancer Cases
      32% Breast
      12% Lung / bronchus
      11% Colon / rectum
      6% Uterine corpus
      4% Non-Hodgkin’s
      4% Melanoma of skin
      3% Ovary
      3% Thyroid
      2% Urinary bladder
      2% Pancreas
      21% All Other Sites
      Prostate 33%
      Lung / bronchus 13%
      Colon / rectum 10%
      Urinary / bladder 7%
      Melanoma of skin 5%
      Non-Hodgkin’s 4%
      Kidney 3%
      Leukemia 3%
      Oral Cavity 3%
      Pancreas 2%
      All Other Sites 17%
      *Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.
      Source: American Cancer Society, 2005.
    • Spontaneous
      UV and ionizing radiation
      Chemical carcinogens
      Tumour induction
      Genetic abnormalities (XP)
      Virus-induced (HepC, EBV, HPV)
      Immunosuppression
      Causative agents
    • History of monoclonal antibody
      The discovery of monoclonal antibodies (mAbs) in 1975 by Kohler and Milstein ushered in cancer treatment to a modern era of targeted therapy . Therapeutic antibodies have become a major strategy in cancer therapy due to their ability to specifically bind to primary and metastatic cancer cells with high affinity
    • The approval of nine mAbs by the FDA for clinical tumor therapy signifies important progress in antibody study. They include
      rituximab (Rituxan®),
      ibritumomab (Zevalin®),
      131I-tositumomab (Bexxar®),
      gemtuzumabozogamicin(Mylotarg
      alemtuzumab (Campath®),
      trastuzumab (Herceptin®)
      bevacizumab (Avastin®),
      cetuximab (Erbitux®)
      panitumumab (Vectibix®).
    • These 9 mAbs can be dividedinto two groups according to their targets
      The first group is directed against antigens that are either specifically expressed by tumor cells, such as the HER-2/neu protein on breast cancer and other carcinomas, or are shared with normal cells, such as differential antigens (CD20, CD52,CD19, etc.).
      The aim of using this type of antibodies is to induce tumor death by neutralizing the effect of a growth factor,
      or by inducing apoptosis,
      or by activating effector mechanisms of the host.
    • The second group of therapeutic mAbs targets the stroma-tumor interactions.
      A leading example of this group is, an mAb that neutralizes vascular endothelial growth factor (VEGF),
      VGEF is a tumor-derived growth factor that increases neo-angiogenesis and thus supports tumor growth.
      mABs Neutralize the VEGF and finally blocks angiogenesis and leads to tumor starvation
    • Since 1997 there have been nine commercially available therapeutic mAbs approved by the FDA
      among which five are being used for treatment of hematologic malignancies
      the other four for solid tumors
    • Rituximab (Rituxan®)
      the commercially most successful anti-cancer drug of all mABs
      Rituximab, which targets the CD20 surface receptor, that is strongly over expressed in most B-cell lymphomas,
      This Rituximab is a chimeric, monoclonal IgG1 antibody that induces apoptosis, antibody-dependent cell cytotoxicity and complement-dependent cytotoxicity.
    • RITUXIMAB ATTACK THE- CD20
    • Rituximab has recently been approved to be administered as either a 4- or 8-dose weekly regimen in patients who have previously responded to rituximab, and in patients who have bulky tumors (>10 cm).
      The overall response rate (ORR) was 50%, with 6% complete response (CR) and 44% partial response (PR) rates
    • Chop followed by rituximab
      the combination of six cycles of chemotherapy consisting of CHOP (cyclophosphamide, adriamycin, oncovin and prednisone) with concurrently administered rituximab in 40 patients with predominantly untreated follicular lymphoma greatly increased the response rate.
      55% CR
      40% PR
    • Side effect of the rituximab
      The main toxicities associated with rituximab included infusion-related chills, fever, nausea, vomiting and general fatigue.
      Bone marrow suppression was not a significant side effect in patients treated with rituximab
    • The combination of anti-angiogenesis mAbs and chemotherapy resulting in synergistic anti-tumor efficacy
      Three distinct mechanisms may help to explain the chemosensitizing activity of anti-angiogenicmAbs:
      1.Normalizing tumor vasculature
      2. preventing rapid increase in tumor cell population
      3. augmenting the antivascular effects of chemotherapy.
    • Antibody gene therapy as a new strategy for cancer treatment
      Although nine mAbs have been approved by the FDA,wider application of mAbs is limited due to the following reasons:
      (1) high dose and purity required for antibody
      protein treatment increase the production cost
      (2) the relatively large molecular weight of full-length antibody and high pressure within the tumor make it difficult for full-length antibody to penetrate into large-volume solid tumors, thus greatly reducing the therapeutic effect
    • Why mABs can not penetrate the solid tumours
      the large molecule full-length antibody has great difficulty entering solid tumors, due to :
      1.compacted stroma within the tumors
      2. high intra-tumor pressure produced by lymphatic return barrier.
      Therefore, the anti-tumor efficacy of conventional antibody therapy is greatly reduced in treating large-volume solid tumors
    • Why adenovirus approved for gene therapy
      we chose adenovirus as the antibody gene transfer vector for the following reasons
      (1) adenovirus has been used in more than 5000 clinical patients without significant adverse effects and toxicity, exhibiting the conclusive safety and efficacy as an in vivo vector
      (2) adenoviral manufacture technologies are easy, convenient and simple
      (3) adenovirus is the only commercial product approved in the world for gene therapy
    • 4. this adenovirus-mediated antibody expressing system could be a new approach for antibody therapy
      5. the complicated, expensive and time-consuming antibody protein preparation and purification procedures could be replaced by using adenovirus as an antibody expression tool for its technical simplicity and low cost
    • Strategy for improving antibody’s anti-tumor effect by exploiting mesenchymal stem cells
      mesenchymal stem cells (MSCs) can recognize the emitting signal from tumors and help to construct matrix or junction tissues for tumor growth, it would be an interesting attempt to use MSCs as a vehicle to deliver full-length antibody to tumors.
      In our study, the bone marrow derived primary mesenchymal stem cells (mBMSCs) were used as a vehicle to target tumor cells (our unpublished data)
    • using MSCs carrying a full-length antibody gene, could overcome the disadvantages of low antibody penetration into solid tumors, markedly enhancing the anti-tumor efficacy and hence it has the potential to be developed into a safe, efficient, low cost and targeting therapeutic system.
    • Antibody gene therapy is less time consuming and more economical compared with traditional antibody protein therapy,
      its potential drawbacks are as follows:
      (1) antibodies from gene therapy are presumably produced in liver and lung cells that are efficiently infected by the viral vector. It is unknown whether some other somatic cells will also express the antibodies
      (2) host antibodies against Adenovirus may decrease the anti-tumor efficacy of virus-mediated full-length antibody gene therapy
    • (3) when this approach is applied to humans, the administration routes, the desired antibody gene expression time and possible inflammation response need to be investigated.
      There is still a long way to go before antibody gene therapy could be put into clinical use.
    • FRIENDLY SHANDONG